Immunoregulatory effects of indoleamine 2, 3-dioxygenase in transplantation

Transplant Immunology

Volumn 21, Issue 1, 2009, Pages 18-22

  Jia, Lining ^a   Tian, Puxun ^a   Ding, Chenguang ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

IDO; Immunoregulation; Transplantation

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; STAT1 PROTEIN; TRYPTOPHAN;

CELL CYCLE PROGRESSION; CELL FUNCTION; CELL INTERACTION; DENDRITIC CELL; ENZYME ACTIVITY; GENE DELETION; GRAFT SURVIVAL; HUMAN; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE PROLIFERATION; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION;

ANIMALS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; TRANSPLANTATION IMMUNOLOGY;

EID: 64049110083     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2009.01.004     Document Type: Review

References (65)

1. Mellor A.L., and Munn D.H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev 4 10 (2004) 762-774
2. Takikawa O. Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated l-tryptophan metabolism. Biochem Biophys Res Commun 338 1 (2005) 12-19
3. Grohmann U., Orabona C., Fallarino F., et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3 11 (2002) 1097-1101
4. Munn D.H., Sharma M.D., Lee J.R., et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science (New York, NY 297 5588 (2002) 1867-1870
5. Fallarino F., Grohmann U., Hwang K.W., et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 4 12 (2003) 1206-1212
6. Manlapat A.K., Kahler D.J., Chandler P.R., Munn D.H., and Mellor A.L. Cell-autonomous control of interferon type I expression by indoleamine 2,3-dioxygenase in regulatory CD19+ dendritic cells. Eur J Immunol 37 4 (2007) 1064-1071
7. Munn D.H., Zhou M., Attwood J.T., et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281 5380 (1998) 1191-1193
8. Munn D.H., and Mellor A.L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117 5 (2007) 1147-1154
9. Choi B.K., Asai T., Vinay D.S., Kim Y.H., and Kwon B.S. 4-1BB-mediated amelioration of experimental autoimmune uveoretinitis is caused by indoleamine 2,3-dioxygenase-dependent mechanisms. Cytokine 34 5-6 (2006) 233-242
10. Boasso A., and Shearer G.M. How does indoleamine 2,3-dioxygenase contribute to HIV-mediated immune dysregulation. Curr Drug Metab 8 3 (2007) 217-223
11. Swanson K.A., Zheng Y., Heidler K.M., Mizobuchi T., and Wilkes D.S. CDllc+ cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenase. Am J Respir Cell Mol Biol 30 3 (2004) 311-318
12. Mellor A.L., and Munn D.H. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev 8 1 (2008) 74-80
13. Ball H.J., Sanchez-Perez A., Weiser S., et al. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 396 1 (2007) 203-213
14. Metz R., Duhadaway J.B., Kamasani U., et al. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 67 15 (2007) 7082-7087
15. Tas S.W., Vervoordeldonk M.J., Hajji N., et al. Noncanonical NF-kappaB signaling in dendritic cells is required for indoleamine 2,3-dioxygenase (IDO) induction and immune regulation. Blood 110 5 (2007) 1540-1549
16. Puccetti P., and Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev 7 10 (2007) 817-823
17. Williams C.A., Harry R.A., and McLeod J.D. Apoptotic cells induce dendritic cell-mediated suppression via interferon-gamma-induced IDO. Immunology 124 1 (2008) 89-101
18. Terness P., Chuang J.J., and Opelz G. The immunoregulatory role of IDO-producing human dendritic cells revisited. Trends Immunol 27 2 (2006) 68-73
19. Baban B., Hansen A.M., Chandler P.R., et al. A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int Immunol 17 7 (2005) 909-919
20. Mellor A.L., Baban B., Chandler P.R., et al. Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol 175 9 (2005) 5601-5605
21. Lee G.K., Park H.J., Macleod M., et al. Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology 107 4 (2002) 452-460
22. Terness P., Bauer T.M., Rose L., et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 196 4 (2002) 447-457
23. Belladonna M.L., Grohmann U., Guidetti P., et al. Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. J Immunol 177 1 (2006) 130-137
24. Fallarino F., Grohmann U., You S., et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 176 11 (2006) 6752-6761
25. Fallarino F., Grohmann U., Vacca C., et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ 9 10 (2002) 1069-1077
26. Munn D.H., Sharma M.D., Baban B., et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22 5 (2005) 633-642
27. Fallarino F., Grohmann U., You S., et al. Tryptophan catabolism generates autoimmune-preventive regulatory T cells. Transpl Immunol 17 1 (2006) 58-60
28. Seymour R.L., Ganapathy V., Mellor A.L., and Munn D.H. A high-affinity, tryptophan-selective amino acid transport system in human macrophages. J Leukoc Biol 80 6 (2006) 1320-1327
29. Keskin D.B., Marshall B., Munn D., Mellor A.L., and Gearhart D.A. Decreased protein nitration in macrophages that overexpress indoleamine 2, 3-dioxygenase. Cell Mol Biol Lett 12 1 (2007) 82-102
30. Latchman Y., Wood C.R., Chernova T., et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2 3 (2001) 261-268
31. Sharma M.D., Baban B., Chandler P., et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 117 9 (2007) 2570-2582
32. Thebault P., Condamine T., Heslan M., et al. Role of IFNgamma in allograft tolerance mediated by CD4+CD25+ regulatory T cells by induction of IDO in endothelial cells. Am J Transplant 7 11 (2007) 2472-2482
33. Bluestone J.A., St Clair E.W., and Turka L.A. CTLA4Ig: bridging the basic immunology with clinical application. Immunity 24 3 (2006) 233-238
34. Vincenti F., Larsen C., Durrbach A., et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 353 8 (2005) 770-781
35. Fallarino F., Vacca C., Orabona C., et al. Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells. Int Immunol 14 1 (2002) 65-68
36. Belladonna M.L., Volpi C., Bianchi R., et al. Cutting edge: autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells. J Immunol 181 8 (2008) 5194-5198
37. Munn D.H., Sharma M.D., and Mellor A.L. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol 172 7 (2004) 4100-4110
38. Hwu P., Du M.X., Lapointe R., et al. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 164 7 (2000) 3596-3599
39. Terness P., Chuang J.J., Bauer T., Jiga L., and Opelz G. Regulation of human auto- and alloreactive T cells by indoleamine 2,3-dioxygenase (IDO)-producing dendritic cells: too much ado about IDO?. Blood 105 6 (2005) 2480-2486
40. Beutelspacher S.C., Pillai R., Watson M.P., et al. Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. Eur J Immunol 36 3 (2006) 690-700
41. Hill M., Tanguy-Royer S., Royer P., et al. IDO expands human CD4+CD25high regulatory T cells by promoting maturation of LPS-treated dendritic cells. Eur J Immunol 37 11 (2007) 3054-3062
42. Thomas S.R., and Stocker R. Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway. Redox Rep 4 5 (1999) 199-220
43. Frumento G., Rotondo R., Tonetti M., et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 196 4 (2002) 459-468
44. Mohib K., Guan Q., Diao H., Du C., and Jevnikar A.M. Proapoptotic activity of indoleamine 2,3-dioxygenase expressed in renal tubular epithelial cells. Am J Physiol Renal Physiol 293 3 (2007) F801-812
45. Mohib K., Wang S., Guan Q., et al. Indoleamine 2,3-dioxygenase expression promotes renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 295 1 (2008) F226-234
46. Thomas S.R., Terentis A.C., Cai H., et al. Post-translational regulation of human indoleamine 2,3-dioxygenase activity by nitric oxide. J Biol Chem 282 33 (2007) 23778-23787
47. Beutelspacher S.C., Tan P.H., McClure M.O., et al. Expression of indoleamine 2,3-dioxygenase (IDO) by endothelial cells: implications for the control of alloresponses. Am J Transplant 6 6 (2006) 1320-1330
48. Liu H., Liu L., Fletcher B.S., and Visner G.A. Novel action of indoleamine 2,3-dioxygenase attenuating acute lung allograft injury. Am J Respir Crit Care Med 173 5 (2006) 566-572
49. Liu H., Liu L., and Visner G.A. Nonviral gene delivery with indoleamine 2,3-dioxygenase targeting pulmonary endothelium protects against ischemia-reperfusion injury. Am J Transplant 7 10 (2007) 2291-2300
50. Miki T., Sun H., Lee Y., et al. Blockade of tryptophan catabolism prevents spontaneous tolerogenicity of liver allografts. Trans Proc 33 1-2 (2001) 129-130
51. Friberg M., Jennings R., Alsarraj M., et al. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer 101 2 (2002) 151-155
52. Li J., Meinhardt A., Roehrich M.E., et al. Indoleamine 2,3-dioxygenase gene transfer prolongs cardiac allograft survival. Am J Physiol Heart Circ Physiol 293 6 (2007) H3415-3423
53. Jalili R.B., Rayat G.R., Rajotte R.V., and Ghahary A. Suppression of islet allogeneic immune response by indoleamine 2,3 dioxygenase-expressing fibroblasts. J Cell Physiol 213 1 (2007) 137-143
54. Mulley W.R., Li Y.Q., Wee J.L., et al. Local expression of IDO, either alone or in combination with CD40Ig, IL10 or CTLA4Ig, inhibits indirect xenorejection responses. Xenotransplantation 15 3 (2008) 174-183
55. Wee J.L., Christiansen D., Li Y.Q., Boyle W., and Sandrin M.S. Suppression of cytotoxic and proliferative xenogeneic T-cell responses by transgenic expression of indoleamine 2,3-dioxygenase. Immunol Cell Biol 86 5 (2008) 460-465
56. Li Y., Tredget E.E., Ghaffari A., et al. Local expression of indoleamine 2,3-dioxygenase protects engraftment of xenogeneic skin substitute. J Invest Dermatol 126 1 (2006) 128-136
57. Li M., Zhang X., Zheng X., et al. Tolerogenic dendritic cells transferring hyporesponsiveness and synergizing T regulatory cells in transplant tolerance. Int Immunol 20 2 (2008) 285-293
58. Cook C.H., Bickerstaff A.A., Wang J.J., et al. Spontaneous renal allograft acceptance associated with "regulatory" dendritic cells and IDO. J Immunol 180 5 (2008) 3103-3112
59. Yu G., Fang M., Gong M., et al. Steady state dendritic cells with forced IDO expression induce skin allograft tolerance by upregulation of regulatory T cells. Transpl Immunol 18 3 (2008) 208-219
60. Yu G., Dai H., Chen J., et al. Gene delivery of indoleamine 2,3-dioxygenase prolongs cardiac allograft survival by shaping the types of T-cell responses. J Gene Med 10 7 (2008) 754-761
61. Lin Y.C., Chen C.L., Nakano T., et al. Immunological role of indoleamine 2,3-dioxygenase in rat liver allograft rejection and tolerance. J Gastroenterol Hepatol 23 7 Pt 2 (2008) e243-50
62. Brandacher G., Cakar F., Winkler C., et al. Non-invasive monitoring of kidney allograft rejection through IDO metabolism evaluation. Kidney Int 71 1 (2007) 60-67
63. Yang H., Ding R., Sharma V.K., et al. Hyperexpression of Foxp3 and IDO during acute rejection of islet allografts. Transplantation 83 12 (2007) 1643-1647
64. Laurence J.M., Wang C., Park E.T., et al. Blocking indoleamine dioxygenase activity early after rat liver transplantation prevents long-term survival but does not cause acute rejection. Transplantation 85 9 (2008) 1357-1361
65. Forouzandeh F., Jalili R.B., Germain M., Duronio V., and Ghahary A. Skin cells, but not T cells, are resistant to indoleamine 2, 3-dioxygenase (IDO) expressed by allogeneic fibroblasts. Wound Repair Regen 16 3 (2008) 379-387